297 related articles for article (PubMed ID: 33414133)
1. ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer.
Mehrvarz Sarshekeh A; Alshenaifi J; Roszik J; Manyam GC; Advani SM; Katkhuda R; Verma A; Lam M; Willis J; Shen JP; Morris J; Davis JS; Loree JM; Lee HM; Ajani JA; Maru DM; Overman MJ; Kopetz S
Clin Cancer Res; 2021 Mar; 27(6):1663-1670. PubMed ID: 33414133
[TBL] [Abstract][Full Text] [Related]
2. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
[TBL] [Abstract][Full Text] [Related]
3. The effects of ARID1A mutations on colorectal cancer and associations with PD-L1 expression by stromal cells.
Kamori T; Oki E; Shimada Y; Hu Q; Hisamatsu Y; Ando K; Shimokawa M; Wakai T; Oda Y; Mori M
Cancer Rep (Hoboken); 2022 Jan; 5(1):e1420. PubMed ID: 34042312
[TBL] [Abstract][Full Text] [Related]
4. The impact of ARID1A mutation on molecular characteristics in colorectal cancer.
Tokunaga R; Xiu J; Goldberg RM; Philip PA; Seeber A; Battaglin F; Arai H; Lo JH; Naseem M; Puccini A; Berger MD; Soni S; Zhang W; Chen S; Hwang JJ; Shields AF; Marshall JL; Baba H; Korn WM; Lenz HJ
Eur J Cancer; 2020 Nov; 140():119-129. PubMed ID: 33080474
[TBL] [Abstract][Full Text] [Related]
5. The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors.
Marisa L; Svrcek M; Collura A; Becht E; Cervera P; Wanherdrick K; Buhard O; Goloudina A; Jonchère V; Selves J; Milano G; Guenot D; Cohen R; Colas C; Laurent-Puig P; Olschwang S; Lefèvre JH; Parc Y; Boige V; Lepage C; André T; Fléjou JF; Dérangère V; Ghiringhelli F; de Reynies A; Duval A
J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922790
[TBL] [Abstract][Full Text] [Related]
6. [Detection and Significance of Molecular Markers in Immunotherapy and Targeted Therapy of Colorectal Cancer in Tibet].
Luo HH; Liu BY; Huo Z; BIANbazhaxi ; Wang Q; DUObula ; NImazhuoma ; DA Z; Wang H; Guo PP
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2024 Apr; 46(2):184-192. PubMed ID: 38686714
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
[TBL] [Abstract][Full Text] [Related]
8.
Li L; Li M; Jiang Z; Wang X
Cells; 2019 Jul; 8(7):. PubMed ID: 31277418
[TBL] [Abstract][Full Text] [Related]
9. Lymphocyte activation gene (LAG)-3 is a potential immunotherapeutic target for microsatellite stable, programmed death-ligand 1 (PD-L1)-positive endometrioid endometrial cancer.
Hong JH; Cho HW; Ouh YT; Lee JK; Chun Y
J Gynecol Oncol; 2023 Mar; 34(2):e18. PubMed ID: 36509464
[TBL] [Abstract][Full Text] [Related]
10. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
[TBL] [Abstract][Full Text] [Related]
11. JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer.
Giordano G; Parcesepe P; D'Andrea MR; Coppola L; Di Raimo T; Remo A; Manfrin E; Fiorini C; Scarpa A; Amoreo CA; Conciatori F; Milella M; Caruso FP; Cerulo L; Porras A; Pancione M
J Exp Clin Cancer Res; 2019 Jan; 38(1):28. PubMed ID: 30670049
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and immune infiltration significance of ARID1A in TCGA molecular subtypes of gastric adenocarcinoma.
Zhang Z; Li Q; Sun S; Ye J; Li Z; Cui Z; Liu Q; Zhang Y; Xiong S; Zhang S
Cancer Med; 2023 Aug; 12(16):16716-16733. PubMed ID: 37366273
[TBL] [Abstract][Full Text] [Related]
13. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
14. Immune overdrive signature in colorectal tumor subset predicts poor clinical outcome.
Fakih M; Ouyang C; Wang C; Tu TY; Gozo MC; Cho M; Sy M; Longmate JA; Lee PP
J Clin Invest; 2019 Oct; 129(10):4464-4476. PubMed ID: 31524634
[TBL] [Abstract][Full Text] [Related]
15. Tumor Infiltrating Lymphocytes and Macrophages Improve Survival in Microsatellite Unstable Colorectal Cancer.
Narayanan S; Kawaguchi T; Peng X; Qi Q; Liu S; Yan L; Takabe K
Sci Rep; 2019 Sep; 9(1):13455. PubMed ID: 31530839
[TBL] [Abstract][Full Text] [Related]
16.
Okamura R; Kato S; Lee S; Jimenez RE; Sicklick JK; Kurzrock R
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32111729
[TBL] [Abstract][Full Text] [Related]
17. Combined prognostic value of CD274 (PD-L1)/PDCDI (PD-1) expression and immune cell infiltration in colorectal cancer as per mismatch repair status.
Ahtiainen M; Wirta EV; Kuopio T; Seppälä T; Rantala J; Mecklin JP; Böhm J
Mod Pathol; 2019 Jun; 32(6):866-883. PubMed ID: 30723299
[TBL] [Abstract][Full Text] [Related]
18. ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application.
Hu G; Tu W; Yang L; Peng G; Yang L
Cancer Lett; 2020 Mar; 473():148-155. PubMed ID: 31911080
[TBL] [Abstract][Full Text] [Related]
19. Multilevel genomics of colorectal cancers with microsatellite instability-clinical impact of JAK1 mutations and consensus molecular subtype 1.
Sveen A; Johannessen B; Tengs T; Danielsen SA; Eilertsen IA; Lind GE; Berg KCG; Leithe E; Meza-Zepeda LA; Domingo E; Myklebost O; Kerr D; Tomlinson I; Nesbakken A; Skotheim RI; Lothe RA
Genome Med; 2017 May; 9(1):46. PubMed ID: 28539123
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression.
Xu SM; Shi CJ; Xia RH; Wang LZ; Tian Z; Ye WM; Liu L; Liu SL; Zhang CY; Hu YH; Zhou R; Han Y; Wang Y; Zhang ZY; Li J
Front Immunol; 2021; 12():798424. PubMed ID: 35145511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
